Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Their focus is on harnessing the power of the body's innate immune system to counteract disease pathology. Alector is developing a portfolio of product candidates designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system, and to counteract the pathology of conditions such as Alzheimer's disease and frontotemporal dementia (FTD). Their approach targets microglia and other immune cells in the brain to restore healthy function and combat neurodegeneration.
Serves as the primary center for Alector's research and development, corporate operations, clinical development, and strategic management. It houses laboratories and office space for scientific and administrative staff.
Located in a major biotechnology hub, providing access to state-of-the-art lab facilities and a collaborative environment. The Oyster Point area is known for its concentration of life science companies.
Alector fosters a science-driven, innovative, and collaborative work culture focused on tackling complex neurodegenerative diseases. Employees are often mission-driven, aiming to make a significant impact on patients' lives.
The South San Francisco location is strategically important due to its proximity to a rich ecosystem of academic institutions, research organizations, talent, and venture capital, crucial for a biotech company.
While Alector's core research, development, and corporate functions are headquartered in South San Francisco, California, its operational reach is global. This is primarily driven by the necessity to conduct multinational clinical trials for its therapeutic candidates. Alector collaborates with clinical research sites, investigators, and contract research organizations (CROs) across North America, Europe, Australia, and potentially other regions to enroll patients and manage studies for diseases like Alzheimer's and frontotemporal dementia. This global trial footprint allows for access to diverse patient populations and accelerates drug development timelines.
151 Oyster Point Blvd, Suite 300
South San Francisco
CA
USA
Address: Not Applicable - Operations largely centralized in South San Francisco HQ.
Support for global clinical trials and collaborations may involve personnel operating remotely or through partners in various regions, rather than through dedicated physical office locations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Alector' leadership includes:
Alector has been backed by several prominent investors over the years, including:
Alector has seen key leadership appointments and transitions over the past year, particularly strengthening its financial and medical teams. Notable changes include a new CFO and CMO, and a transition in the Head of R&D role.
Discover the tools Alector uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Alector commonly uses the email format of the employee's first initial followed by their last name. Other formats might exist but this is the most frequently observed pattern.
[first_initial][last]@alector.com
Format
jdoe@alector.com
Example
80%
Success rate
GlobeNewswire • May 9, 2024
Alector announced its Q1 2024 financial results, highlighting progress in its clinical programs, including latozinemab (AL001) for FTD-GRN, AL002 for early Alzheimer's disease, and AL101 for Alzheimer's and Parkinson's diseases. The company provided updates on its collaborations, including with GSK and AbbVie, and outlined upcoming milestones....more
GlobeNewswire • April 3, 2024
Alector announced its participation in the 23rd Annual Needham Virtual Healthcare Conference and the Stifel 2024 Targeted SBER Forum, indicating ongoing engagement with the investment community to discuss company progress and strategy....more
GlobeNewswire • February 27, 2024
Alector provided its Q4 and full-year 2023 financial results, detailing advancements in its immuno-neurology pipeline and collaborations. Key updates included progress on Phase 3 study of latozinemab for FTD-GRN and initiation of AL101 Phase 2 study in Parkinson's disease....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Alector, are just a search away.